|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Cash flows - operating activities | |||
| Net income | |||
| Less: Income (loss) from discontinued operations, net of taxes | |||
| Net income from continuing operations | |||
| Adjustments to reconcile Net income to Cash from (used for) operating activities – continuing operations: | |||
| Depreciation of property, plant, and equipment | |||
| Amortization of intangible assets | |||
| Gain on fair value remeasurement of contingent consideration | |||
| Gain on remeasurement of Nihon Medi-Physics equity method investment | |||
| Net periodic postretirement benefit plan (income) expense | |||
| Postretirement plan contributions | |||
| Share-based compensation | |||
| Provision for income taxes | |||
| Cash paid during the year for income taxes | |||
| Changes in operating assets and liabilities, excluding the effects of acquisitions: | |||
| Receivables | |||
| Due from related parties | |||
| Inventories | |||
| Contract and other deferred assets | |||
| Accounts payable | |||
| Due to related parties | |||
| Contract liabilities | |||
| Current compensation and benefits | |||
| All other operating activities – net | |||
| Cash from (used for) operating activities – continuing operations | |||
| Cash flows – investing activities | |||
| Additions to property, plant and equipment and internal-use software | |||
| Dispositions of property, plant, and equipment | |||
| Purchases of businesses, net of cash acquired | |||
| Purchases of investments | |||
| All other investing activities – net | |||
| Cash from (used for) investing activities – continuing operations | |||
| Cash flows – financing activities | |||
| Net increase (decrease) in borrowings (maturities of 90 days or less) | |||
| Newly issued debt, net of debt issuance costs (maturities longer than 90 days) | |||
| Repayments and other reductions (maturities longer than 90 days) | |||
| Dividends paid to stockholders | |||
| Repurchase of common stock | |||
| Redemption of noncontrolling interests | |||
| Net transfers (to) from GE | |||
| Proceeds from stock issued under employee benefit plans | |||
| Taxes paid related to net share settlement of equity awards | |||
| All other financing activities – net | |||
| Cash from (used for) financing activities – continuing operations | |||
| Cash from (used for) operating activities – discontinued operations | |||
| Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash | |||
| Increase (decrease) in cash, cash equivalents, and restricted cash | |||
| Cash, cash equivalents, and restricted cash at beginning of year | |||
| Cash, cash equivalents, and restricted cash at end of year | |||
| Supplemental disclosure of cash flows information | |||
| Cash paid during the year for interest | |||
| Non-cash investing activities | |||
| Acquired but unpaid property, plant, and equipment |
Loading...
